Search

Your search keyword '"Eghtesad, B."' showing total 309 results
Start Over Author "Eghtesad, B."

Refine your results

more »

more »

more »
309 results on '"Eghtesad, B."'

1. Integration of machine perfusion in a liver transplant program reduces waitlist time and mortality

Author

Wehrle, C.J., primary, Hong, H., additional, Gross, A., additional, Liu, Q., additional, Ali, K., additional, Cazzaniga, B., additional, Miyazaki, Y., additional, Tuul, M., additional, Wakam, G., additional, Fairchild, R., additional, Modaresi Esfeh, J., additional, Khalil, M., additional, Pita, A., additional, Kim, J., additional, Diago-Uso, T., additional, Aucejo, F., additional, Kwon, D.C.H., additional, Eghtesad, B., additional, Fujiki, M., additional, Quintini, C., additional, Schlegel, A., additional, Pinna, A., additional, Miller, C., additional, and Hashimoto, K., additional

Published
2024
Full Text
View/download PDF

23. Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir

Author

Ascha, Mustafa, Ascha, Mona, Zein, N. N., Alkhouri, N., Eghtesad, B., Abu-Elmagd, K., Diago, T., and Hanouneh, I. A.

Subjects
surgical procedures, operative, Liver transplantation, Genotype, Interferon, Case Series, Hepacivirus
Abstract

Hepatitis C virus (HCV) infection remains a leading indication for orthotopic liver transplantation (OLT) worldwide. Recurrence of HCV following OLT is universal. There is scarcity of data on the post-OLT treatment of HCV genotype-4—the predominant genotype in North Africa and the Middle East. Herein, we present three patients who have experienced HCV genotype-4 recurrence post-OLT. All three patients were interferon-naive and were treated with simeprivir (SIM) and sofosbuvir (SOF) combination therapy for 12–24 weeks. The data from this case series show that SIM+SOF are well-tolerated and effective for achieving viral clearance in HCV genotype-4 post-OLT patients. Given the limited nature of a case series, further research must be pursued regarding post-OLT HCV genotype-4 responses to direct-acting anti-viral therapy.

Published
2015

26. Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection

Author

Hanouneh, I. A., Macaron, C., Lopez, R., Feldstein, A. E., Yerian, L., Eghtesad, B., and Zein, N. N.

Subjects
surgical procedures, operative, Hepatitis C virus, Original Article, Nonalcoholic steatohepatitis, Orthotopic liver transplantation, Prognosis, digestive system diseases
Abstract

Background: Nonalcoholic steatohepatitis (NASH) is an increasing indication for orthotopic liver transplantation (OLT) in the United States and other countries. However, the incidence of disease recurrence and natural course following OLT remains incompletely understood. Objective: To estimate the incidence of recurrent disease, outcome and identify risk factors associated with disease recurrence in patients undergoing OLT for NASH as compared to those undergoing OLT for HCV cirrhosis. Methods: We identified all patients with end-stage liver disease secondary to NASH (n=53) or HCV (n=95) cirrhosis who underwent OLT at our institution between 1998 and 2005. Protocol liver biopsies were performed (Day 7, Month 4 and yearly) after OLT, and as clinically indicated. Kaplan-Meier survival analysis was performed to assess the fibrosis progression and survival. Cox regression analysis was performed to identify factors associated with disease recurrence. Results: Five-year survival was 90.5% in NASH vs 88.4% in HCV group (p=0.97). The median (25%ile, 75%ile) follow-up to last available biopsy was 12.7 (5.9, 26.3) months, during which 17 (32%) of NASH patients developed persistent fatty infiltration in their graft, 8 (15%) of whom had accompanying histologic features of recurrent NASH. There was no difference in the prevalence of post-OLT steatosis between HCV and NASH patients after adjusting for time of histologic follow-up (p=0.33). Patients with HCV infection were more likely to develop hepatic fibrosis post-OLT than those with NASH (62.1% vs 18.9%, p

Published
2011

27. IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens

Author

Ia, Hanouneh, Nn, Zein, Lopez R, Yerian L, John Fung, and Eghtesad B

Subjects
hepatitis C virus, Transplantation, interleukin receptor antagonist, cirrhosis, Original Article, liver, liver fibrosis
Abstract

Background: Recurrence of hepatitis C virus (HCV) infection following orthotopic liver transplantation (OLT) is universal. There is paucity of data on the safety and efficacy of interleukin (IL)-2 receptor antagonist (IL-2RA) when added to the standard immunosuppression regimen in OLT recipients with recurrent HCV infection. Objectives: To evaluate the efficacy of IL-2RA (Basiliximab) in preventing acute cellular rejection (ACR) in patients with recurrent HCV infection after OLT and to assess the impact of IL-2RA in promoting fibrosis progression in post-OLT recurrent HCV infection. Methods: Using an electronic pathology database, we identified all OLT/HCV patients with at least 2 post-OLT liver biopsies (1998–2006). Standard immunosuppression consisted of steroids and calcineurin inhibitor with and without mycophenolate mofetil. All patients who were transplanted after May 2004 received IL-2RA induction therapy. The Ludwig-Batts system was used to stage all biopsies (593 biopsies from 124 patients). The first biopsy that showed post-OLT fibrosis or the last follow-up biopsy was used for time-to-progression analysis. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify factors associated with the progression of fibrosis. Results: ACR was significantly (p

Published
2010

32. Concurrent Umbilical Hernia Repair at the Time of Liver Transplantation: A Six-Year Experience from a Single Institution.

Author

Perez, A. J., Haskins, I. N., Prabhu, A. S., Krpata, D. M., Tu, C., Rosenblatt, S., Hashimoto, K., Diago, T., Eghtesad, B., and Rosen, M. l. J.

Subjects
LIVER transplantation, UMBILICAL hernia, SURGICAL site, DISEASE relapse, HEALTH outcome assessment, THERAPEUTICS
Abstract

Background: Umbilical hernias are common in patients with end-stage liver disease undergoing liver transplantation. Management of those persisting at the time of liver transplantation is important to define. Objective: To evaluate the long-term results of patients undergoing simultaneous primary umbilical hernia repair (UHR) at the time of liver transplantation at a single institution. Methods: Retrospective chart review was performed on patients undergoing simultaneous UHR and liver transplantation from 2010 through 2016. 30-day morbidity and mortality outcomes and long-term hernia recurrence were investigated. Results: 59 patients had primary UHR at the time of liver transplantation. All hernias were reducible with no overlying skin breakdown or leakage of ascites. 30-day morbidity and mortality included 5 (8%) superficial surgical site infections, 1 (2%) deep surgical site infection, and 7 (12%) organ space infections. Unrelated to the UHR, 10 (17%) patients had an unplanned return to the operating room, 16 (27%) were readmitted within 30 days of their index operation, and 1 (2%) patient died. With a mean follow-up of 21.8 months, 7 (18%) patients experienced an umbilical hernia recurrence. Conclusion: Despite the high perioperative morbidity associated with the transplant procedure, concurrent primary UHR resulted in an acceptable long-term recurrence rate with minimal associated morbidity. [ABSTRACT FROM AUTHOR]

Published
2018

37. Liver Transplantation Using Anti-HBc Positive Donors: A Single Center Experience.

Author

Bollinger, J., primary, Plavney, D., additional, Zein, N., additional, Hashimoto, K., additional, Diago, T., additional, Kelly, D., additional, Quintini, C., additional, Aucejo, F., additional, Fujiki, M., additional, Winans, C., additional, Kerepesi, K., additional, Waby, A., additional, Miller, C., additional, Fung, J., additional, and Eghtesad, B., additional

Published
2014
Full Text
View/download PDF

38. Normothermic Machine Perfusion (NMP) Promotes Early Graft Function and Biliary Epithelial Regeneration After Transplantation of Porcine Livers Undergoing 1hr Warm Ischemia (WI).

Author

Liu, Q., primary, Nassar, A., additional, Kelly, D., additional, Hashimoto, K., additional, Eghtesad, B., additional, Uso, Diago T., additional, Irefin, S., additional, Cywinski, J., additional, Baldwin, W., additional, Fung, J., additional, Abu-Elmagd, K., additional, Charles, M., additional, and Quintini, C., additional

Published
2014
Full Text
View/download PDF

39. Induction With Anti-Thymocyte Globulin (r-ATG) and Delayed Calcineurin Inhibitor Therapy in Patients With Acute Renal Failure Dysfunction Pre-Liver Transplant Allows for Sustained Renal Recovery Post Transplant.

Author

Presser, N., primary, Watson, M., additional, Bollinger, J., additional, Fujiki, M., additional, Diago, T., additional, Aucjeo, F., additional, Quintini, C., additional, Hashimoto, K., additional, Kelly, D., additional, Winans, C., additional, Miller, C., additional, Fung, J., additional, and Eghtesad, B., additional

Published
2014
Full Text
View/download PDF

41. Liver Transplantation Using Pediatric Organ Donation After Circulatory Death - An Analysis of the National Registry.

Author

El-Gazzaz, G., primary, Schold, J., additional, Nazzal, M., additional, Kawamura, N., additional, Spagiari, M., additional, Hashimoto, K., additional, Quintini, C., additional, Aucejo, F., additional, Kelly, D., additional, Fujiki, M., additional, Winans, C., additional, Diago, T., additional, Miller, C., additional, Fung, J., additional, and Eghtesad, B., additional

Published
2014
Full Text
View/download PDF

44. Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.

Author

Issa, D., Eghtesad, B., Zein, N. N., Yerian, L., Cruise, M., Alkhouri, N., Adams, R., and Hanouneh, I. A.

Subjects
*HEPATITIS C treatment, *DISEASE relapse, *LIVER injuries, *HEPATITIS C virus, *LIVER transplantation, *ANTIVIRAL agents
Abstract

Fibrosing cholestatic hepatitis (FCH) is an aggressive form of hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT), which frequently results in graft failure and death. Treatment of FCH remains challenging, and the optimal antiviral therapy is yet to be determined. Between November 2013 and early 2015, 62 patients with HCV cirrhosis underwent OLT at our transplant center, of whom, 5 patients developed recurrence HCV in the form of severe FCH and were treated with sofosbuvir and simeprevir (SOF-SMV) for 24 weeks. All patients achieved significant improvement of HCV viral load and had undetectable viral PCR at 6-8 week of treatment. The HCV RNA remained undetectable throughout treatment course. The first two patients achieved SVR at week 12 after completion of the treatment. There were significant histologic and biomarkers improvements after initiation of the treatment. One patient developed refractory pruritus and acute pancreatitis. The second, fourth and fifth patients had very benign treatment courses with no side effects recorded. The third patient was starting the treatment with multiple comorbid conditions. His course was complicated with hepatic artery thrombosis, and later developed sepsis and renal failure. Therefore, it seems that the combination of SOF-SMV is an efficacious oral regimen in OLT recipient with recurrent hepatitis C and FCH. However, safety profile needs to be carefully evaluated. [ABSTRACT FROM AUTHOR]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results